CD33 and acute myeloid leukemia: 225Ac‐lintuzumab is a clinical stage radioimmunotherapy targeting CD33 that has shown evidence of single‐agent activity in relapsed/refractory AML17, 18, 19 and is being actively investigated in combination clinical studies in the treatment of relapsed or refractory AML.